

Laura K Ferris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8617365/publications.pdf>

Version: 2024-02-01

75
papers

2,427
citations

186265

28
h-index

214800

47
g-index

76
all docs

76
docs citations

76
times ranked

3371
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. <i>Dermatology and Therapy</i> , 2022, 12, 561-575.	3.0	7
2	Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a <i>post hoc</i> integrated analysis of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 855-865.	2.4	11
3	Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System. <i>JAMA Dermatology</i> , 2022, 158, 504.	4.1	26
4	Utilization of Asynchronous and Synchronous Teledermatology in a Large Health Care System During the COVID-19 Pandemic. <i>Telemedicine Journal and E-Health</i> , 2021, 27, 771-777.	2.8	44
5	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	7.0	53
6	Dermoscopy Proficiency Expectations for US Dermatology Resident Physicians. <i>JAMA Dermatology</i> , 2021, 157, 189.	4.1	4
7	Melanoma toolkit for early detection for primary care providers: A pilot study. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 984-986.	3.3	3
8	Early Detection of Melanoma. <i>JAMA Dermatology</i> , 2021, 157, 511.	4.1	6
9	Cost of Treatment of Benign and Premalignant Lesions During Skin Cancer Screening. <i>JAMA Dermatology</i> , 2021, 157, 876-879.	4.1	2
10	Electrophilic nitro-fatty acids suppress psoriasiform dermatitis: STAT3 inhibition as a contributory mechanism. <i>Redox Biology</i> , 2021, 43, 101987.	9.0	11
11	COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1274-1284.	1.2	82
12	Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 152-159.	2.2	38
13	Thick melanoma is associated with low melanoma knowledge and low perceived health competence, but not delays in care. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 587-590.	1.2	1
14	Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1023-1024.	1.2	14
15	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blind trial. <i>British Journal of Dermatology</i> , 2020, 182, 1348-1358.	1.5	117
16	Quality of Life Assessed Using Skindex-16 Scores Among Patients With Acne Receiving Isotretinoin Treatment. <i>JAMA Dermatology</i> , 2020, 156, 1098.	4.1	14
17	Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical Companies. <i>JAMA Dermatology</i> , 2020, 156, 1136.	4.1	4
18	Reply to: "Comment on "Re-evaluating the ABCD criteria using a consecutive series of melanomas". <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e299.	1.2	1

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	3.0	40
20	Re-evaluating the ABCD criteria using a consecutive series of melanomas. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1161-1163.	1.2	6
21	Screening and Managing Melanoma: Who Is (Should Be) Doing It?. <i>Current Dermatology Reports</i> , 2019, 8, 164-171.	2.1	0
22	Benefits to patient care of electronically capturing patient-reported outcomes in dermatology. <i>British Journal of Dermatology</i> , 2019, 181, 826-827.	1.5	9
23	Noninvasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1127-1134.	0.7	19
24	Psychosocial impact of skin biopsies in the setting of melanoma screening: a cross-sectional survey. <i>British Journal of Dermatology</i> , 2019, 180, 664-665.	1.5	2
25	Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study. <i>Dermatology Online Journal</i> , 2019, 25, .	0.5	4
26	Accuracy of Skin Cancer Diagnosis by Physician Assistants Compared With Dermatologists in a Large Health Care System. <i>JAMA Dermatology</i> , 2018, 154, 569.	4.1	67
27	Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 755-760.	2.3	18
28	Estimating the cost of skin cancer detection by dermatology providers in a large health care system. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 701-709.e1.	1.2	38
29	Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2729-2739.	2.3	11
30	Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. <i>Cancer Prevention Research</i> , 2018, 11, 429-438.	1.5	59
31	The Value of Behavioral Counseling for Skin Cancer Prevention. <i>JAMA Oncology</i> , 2018, 4, 630.	7.1	2
32	Topical electrophilic nitro-fatty acids potentiate cutaneous inflammation. <i>Free Radical Biology and Medicine</i> , 2018, 115, 31-42.	2.9	11
33	Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins. <i>JAMA Dermatology</i> , 2018, 154, 1401.	4.1	30
34	Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2564-2572.	2.3	6
35	Performance of Dermatology Physician Assistants' Reply. <i>JAMA Dermatology</i> , 2018, 154, 1229.	4.1	0
36	Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. <i>BMC Cancer</i> , 2018, 18, 130.	2.6	117

#	ARTICLE	IF	CITATIONS
37	Psychosocial consequences of skin cancer screening. <i>Preventive Medicine Reports</i> , 2018, 10, 310-316.	1.8	20
38	Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions. <i>Melanoma Research</i> , 2018, 28, 478-482.	1.2	47
39	Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 818-825.e3.	1.2	44
40	A Large Skin Cancer Screening Quality Initiative. <i>JAMA Oncology</i> , 2017, 3, 1112.	7.1	50
41	Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy. <i>JAMA Dermatology</i> , 2017, 153, 675.	4.1	64
42	Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). <i>British Journal of Dermatology</i> , 2017, 177, 1552-1561.	1.5	44
43	BAP1 regulates IP3R3-mediated Ca ²⁺ flux to mitochondria suppressing cell transformation. <i>Nature</i> , 2017, 546, 549-553.	27.8	308
44	Nonmelanoma skin cancer and risk of all-cause and cancer-related mortality: a systematic review. <i>Archives of Dermatological Research</i> , 2017, 309, 243-251.	1.9	62
45	A cross-sectional study of indoor tanning use among patients seeking skin cancer screening. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 164-165.	1.2	3
46	Smartphone-Based Applications for Skin Monitoring and Melanoma Detection. <i>Dermatologic Clinics</i> , 2017, 35, 551-557.	1.7	62
47	The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 667-674.	1.2	89
48	Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 114-120.e2.	1.2	107
49	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 432-440.e17.	1.2	111
50	Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules. <i>Molecular Medicine Reports</i> , 2016, 14, 3935-3940.	2.4	20
51	A Systematic Review of Concomitant Bullous Pemphigoid and Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 1, 150-158.	0.7	2
52	Downstream consequences of melanoma screening in a community practice setting: First results. <i>Cancer</i> , 2016, 122, 3152-3156.	4.1	35
53	Reply to: "Computer-aided classification of melanocytic lesions using dermoscopic images: Low reported accuracy for reader study on melanomas with low melanoma in situ to invasive melanoma ratio". <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e121.	1.2	1
54	Patient Preferences During Skin Cancer Screening Examination. <i>JAMA Dermatology</i> , 2016, 152, 1052.	4.1	14

#	ARTICLE	IF	CITATIONS
55	Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients.. Journal of Clinical Oncology, 2016, 34, 9581-9581.	1.6	9
56	Dose-response evaluation of broccoli sprout extract sulforaphane (BSE-SFN) in melanoma patients (Pts) with atypical/dysplastic nevi (A/DN).. Journal of Clinical Oncology, 2016, 34, e21022-e21022.	1.6	5
57	Preliminary outcomes of a primary care-based skin cancer screening program.. Journal of Clinical Oncology, 2016, 34, 1508-1508.	1.6	1
58	Correlation Between the Evaluation of Pigmented Lesions by a Multi-spectral Digital Skin Lesion Analysis Device and the Clinical and Histological Features of Melanoma. Journal of Clinical and Aesthetic Dermatology, 2016, 9, 36-8.	0.1	1
59	A pragmatic approach to melanoma screening in collaboration with primary care providers. Cutis, 2016, 97, 382-3.	0.3	0
60	We Pledge to Change iPLEDGE. JAMA Dermatology, 2015, 151, 701.	4.1	8
61	Immunosuppression is an independent prognostic factor associated with aggressive tumor behavior in cutaneous melanoma. Journal of the American Academy of Dermatology, 2015, 73, 461-466.	1.2	7
62	Indoor Tanning, Skin Cancer and the Young Female Patient: A Review of the Literature. Journal of Pediatric and Adolescent Gynecology, 2015, 28, 275-283.	0.7	17
63	Promoting Safe Use of Isotretinoin by Increasing Contraceptive Knowledge. JAMA Dermatology, 2015, 151, 389.	4.1	12
64	Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. Journal of the American Academy of Dermatology, 2015, 72, 780-785.e3.	1.2	148
65	Computer-aided classification of melanocytic lesions using dermoscopic images. Journal of the American Academy of Dermatology, 2015, 73, 769-776.	1.2	79
66	Women's Experiences With Isotretinoin Risk Reduction Counseling. JAMA Dermatology, 2014, 150, 366.	4.1	18
67	Melanoma depth in patients with an established dermatologist. Journal of the American Academy of Dermatology, 2014, 70, 841-846.	1.2	13
68	Epidemiology of Ophthalmologic Disease Associated with Erythema Multiforme, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis in Hospitalized Children in the United States. Pediatric Dermatology, 2014, 31, 163-168.	0.9	18
69	Predictors of thick and lethal melanoma in white young adults in the United States. Journal of the American Academy of Dermatology, 2014, 70, 198-200.	1.2	0
70	Efficacy, Safety, and Out-of-pocket Costs are the Most Important Factors to Patients in Choosing a Psoriasis Therapy. Journal of Clinical and Aesthetic Dermatology, 2014, 7, 30-3.	0.1	47
71	Human Beta-Defensin 3 Induces Maturation of Human Langerhans Cell-Like Dendritic Cells: An Antimicrobial Peptide that Functions as an Endogenous Adjuvant. Journal of Investigative Dermatology, 2013, 133, 460-468.	0.7	53
72	Could testing for BAP1 germline mutations be a useful tool for early melanoma diagnosis?. Expert Review of Dermatology, 2013, 8, 107-109.	0.3	1

#	ARTICLE	IF	CITATIONS
73	Should there be an app for that? Controversies of diagnosing melanoma with your smartphone. Expert Review of Dermatology, 2013, 8, 221-223.	0.3	0
74	Surveillance of Patients for Early Detection of Melanoma. Archives of Dermatology, 2011, 147, 673.	1.4	29
75	Mutations in the SC4MOL gene encoding a novel methyl sterol oxidase cause autosomal recessive psoriasisiform dermatitis, microcephaly and developmental delay. Nature Precedings, 2008, , .	0.1	1